This report contains market size and forecasts of Graft Versus Host Disease Treatment in Global, including the following market information:
Global Graft Versus Host Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Graft Versus Host Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Etanercept Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Graft Versus Host Disease Treatment include AbbVie Inc., Acrofan, Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, F. Hoffmann-La Roche AG, Johnson & Johnson, Mallinckrodft PLC and Merck & Co., Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Graft Versus Host Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Graft Versus Host Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Graft Versus Host Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Global Graft Versus Host Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Graft Versus Host Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
Global Graft Versus Host Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Graft Versus Host Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Graft Versus Host Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Graft Versus Host Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.